Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors
Abstract Developing therapeutics that target multiple receptor signaling pathways in tumors is critical as therapies targeting single specific biomarker/pathway have shown limited efficacy in patients with cancer. In this study, we extensively characterized a bi-functional molecule comprising of epi...
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2012dc1702134a00bc4fa931d84efa4f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:2012dc1702134a00bc4fa931d84efa4f |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:2012dc1702134a00bc4fa931d84efa4f2021-12-02T12:30:37ZBi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors10.1038/s41598-017-02483-92045-2322https://doaj.org/article/2012dc1702134a00bc4fa931d84efa4f2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02483-9https://doaj.org/toc/2045-2322Abstract Developing therapeutics that target multiple receptor signaling pathways in tumors is critical as therapies targeting single specific biomarker/pathway have shown limited efficacy in patients with cancer. In this study, we extensively characterized a bi-functional molecule comprising of epidermal growth factor receptor (EGFR) targeted nanobody (ENb) and death receptor (DR) targeted ligand TRAIL (ENb-TRAIL). We show that ENb-TRAIL has therapeutic efficacy in tumor cells from different cancer types which do not respond to either EGFR antagonist or DR agonist monotherapies. Utilizing pharmacological inhibition, genetic loss of function and FRET studies, we show that ENb-TRAIL blocks EGFR signalling via the binding of ENb to EGFR which in turn induces DR5 clustering at the plasma membrane and thereby primes tumor cells to caspase-mediated apoptosis. In vivo, using a clinically relevant orthotopic resection model of primary glioblastoma and engineered stem cells (SC) expressing ENb-TRAIL, we show that the treatment with synthetic extracellular matrix (sECM) encapsulated SC-ENb-TRAIL alleviates tumor burden and significantly increases survival. This study is the first to report novel mechanistic insights into simultaneous targeting of receptor-mediated proliferation and cell death signaling pathways in different tumor types and presents a promising approach for translation into the clinical setting.Yanni ZhuNicole BassoffClemens ReinshagenDeepak BhereMichal O. NowickiSean E. LawlerJérémie RouxKhalid ShahNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Yanni Zhu Nicole Bassoff Clemens Reinshagen Deepak Bhere Michal O. Nowicki Sean E. Lawler Jérémie Roux Khalid Shah Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
description |
Abstract Developing therapeutics that target multiple receptor signaling pathways in tumors is critical as therapies targeting single specific biomarker/pathway have shown limited efficacy in patients with cancer. In this study, we extensively characterized a bi-functional molecule comprising of epidermal growth factor receptor (EGFR) targeted nanobody (ENb) and death receptor (DR) targeted ligand TRAIL (ENb-TRAIL). We show that ENb-TRAIL has therapeutic efficacy in tumor cells from different cancer types which do not respond to either EGFR antagonist or DR agonist monotherapies. Utilizing pharmacological inhibition, genetic loss of function and FRET studies, we show that ENb-TRAIL blocks EGFR signalling via the binding of ENb to EGFR which in turn induces DR5 clustering at the plasma membrane and thereby primes tumor cells to caspase-mediated apoptosis. In vivo, using a clinically relevant orthotopic resection model of primary glioblastoma and engineered stem cells (SC) expressing ENb-TRAIL, we show that the treatment with synthetic extracellular matrix (sECM) encapsulated SC-ENb-TRAIL alleviates tumor burden and significantly increases survival. This study is the first to report novel mechanistic insights into simultaneous targeting of receptor-mediated proliferation and cell death signaling pathways in different tumor types and presents a promising approach for translation into the clinical setting. |
format |
article |
author |
Yanni Zhu Nicole Bassoff Clemens Reinshagen Deepak Bhere Michal O. Nowicki Sean E. Lawler Jérémie Roux Khalid Shah |
author_facet |
Yanni Zhu Nicole Bassoff Clemens Reinshagen Deepak Bhere Michal O. Nowicki Sean E. Lawler Jérémie Roux Khalid Shah |
author_sort |
Yanni Zhu |
title |
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
title_short |
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
title_full |
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
title_fullStr |
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
title_full_unstemmed |
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
title_sort |
bi-specific molecule against egfr and death receptors simultaneously targets proliferation and death pathways in tumors |
publisher |
Nature Portfolio |
publishDate |
2017 |
url |
https://doaj.org/article/2012dc1702134a00bc4fa931d84efa4f |
work_keys_str_mv |
AT yannizhu bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT nicolebassoff bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT clemensreinshagen bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT deepakbhere bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT michalonowicki bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT seanelawler bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT jeremieroux bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors AT khalidshah bispecificmoleculeagainstegfranddeathreceptorssimultaneouslytargetsproliferationanddeathpathwaysintumors |
_version_ |
1718394320865722368 |